Rapport Therapeutics aims to transform the treatment of neurological and psychiatric disorders through precision neuromedicine. The company's proprietary RAP technology platform identifies and targets receptor-associated proteins, allowing its small molecule candidates to act selectively on specific neural circuits to minimize widespread side effects. Its lead product candidate, RAP-219, is an investigational drug designed to treat drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain. The company is also advancing other discovery-stage programs, including RAP-199 and nicotinic acetylcholine receptor (nAChR) modulators for chronic pain and hearing disorders. Rapport was established in 2022 through a collaboration between Third Rock Ventures and Johnson & Johnson Innovation.
